Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

Lindsey E. Roeker, MD, Jennifer R. Brown, MD PhD, Peter Dreger, Oscar B Lahoud, MD, Toby A. Eyre, MBBChir, MRCP, Danielle M. Brander, MD, Alan Skarbnik, MD, Catherine C. Coombs, MD, Haesook T. Kim, PhD, Steven T Manchini, BS, Timothy J Voorhees, MD, Kim H. Orchard, MBBS,PhDFRCP,FRCPath, Harriet S Walter, Arvind K. Arumainathan, FRCPath, MBBS, MRCP,, Andrea Sitlinger, MD, Craig S. Sauter, MD, Sergio A Giralt, MD, Miguel-Angel Perales, MD, Anthony R. Mato, MDMSCE

Blood (2019) 134 (Supplement_1): 3321.

https://doi.org/10.1182/blood-2019-124140

Published: 2019

Journal Articles

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Anthony R. Mato, MDMSCE, Lindsey E. Roeker, MD, Toby A. Eyre, MBBChir, MRCP, Ryan Jacobs, MD, Brian T. Hill, MD, Nicole Lamanna, MD, Danielle M. Brander, MD, Mazyar Shadman, MD, Chaitra Ujjani, MD, Maryam Yazdy, MD, Guilherme Fleury Perini, MD, Javier Pinilla Ibarz, MD PhD, Jacqueline C Barrientos, MD, Alan Skarbnik, MD, Pallawi Torka, MD, Jeffrey J Pu, MD PhD, John M. Pagel, MD PhD DSc, Satyen Gohil, BSc, MBBS, MRCP, FRCPath, Bita Fakhri, MDMPH, Michael Y. Choi, MD, Catherine C. Coombs, MD, Joanna Rhodes, MD, Paul M. Barr, MD, Craig A. Portell, MD, Helen Parry, MB ChB, MRCP, PhD, Christine Ann Garcia, MD MPH, Kate J Whitaker, BA, Allison M. Winter, MD, Andrea Sitlinger, MD, Sirin Khajavian, MD, Ariel F Grajales-Cruz, MD, Krista Isaac, DO, MS, Pratik Shah, Othman S. Akhtar, MD, Rachael Pocock, MD, Kentson Lam, MD PhD, Timothy J Voorhees, MD, Stephen J. Schuster, MD, Thomas David Rodgers, MD, Nicolas Martinez-Calle, MD MSc, Talha Munir, MD, Erica B Bhavsar, BS, Neil Bailey, MSc, Jason C. Lee, MD, Hanna Weissbrot, BS, Chadi Nabhan, MDMBA, FACP, Julie Goodfriend, Amber C. King, PharmD, BCOP, Andrew D. Zelenetz, MD PhD, Colleen Dorsey, BSN, RN, Kayla Bigelow, Bruce D. Cheson, MD, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 502.

https://doi.org/10.1182/blood-2019-123747

Published: 2019

Journal Articles

Idelalisib-Rituximab Results in Considerable Toxicity but Induces Durable Clinical Remissions in Patients with TP53 Disrupted B Cell Prolymphocytic Leukemia

Toby A. Eyre, MBBChir, MRCP, Christopher P. Fox, MBChB, PhD, Ali Boden, MRCP, Adrian Bloor, Moez Dungawalla, Paneesha Shankara, Richard Went, Anna Schuh, MD PhD

Blood (2017) 130 (Supplement 1): 4068.

https://doi.org/10.1182/blood.V130.Suppl_1.4068.4068

Published: 2017

Journal Articles

18 f-FDG PET-CT Assessment of Responses to Salvage Therapy and Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)

Maciej Tatarczuch, BMBS, FRACP, FRCPA, Catherine Hildyard, MRCP, BA, Manil Subesinghe, MBBS, MRCP, FRCR., Toby A. Eyre, MBBChir, MRCP, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 5181.

https://doi.org/10.1182/blood.V130.Suppl_1.5181.5181

Published: 2017

Journal Articles

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Toby A. Eyre, MBBChir, MRCP, Catherine Hildyard, MRCP, BA, Anesh Panchal, BSc, MSc, Aimee E Houlton, BSc, MSc, Louise Hopkins, BSc, MRes, Angela Hamblin, MD PhD, Kim Linton, MBChB PhD, Andrew Pettitt, FRCPath, PhD, Simon Rule, MD, Kate Cwynarski, PhD MD, Sally Barrington, MBBS, MSc, FRCP, FRCR, MD, David Wrench, MA, MBBChir, FRCPath, PhD, Andrew Davies, PhD, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 5210.

https://doi.org/10.1182/blood.V130.Suppl_1.5210.5210

Published: 2017

NARROW

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Idelalisib-Rituximab Results in Considerable Toxicity but Induces Durable Clinical Remissions in Patients with TP53 Disrupted B Cell Prolymphocytic Leukemia

18 f-FDG PET-CT Assessment of Responses to Salvage Therapy and Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Idelalisib-Rituximab Results in Considerable Toxicity but Induces Durable Clinical Remissions in Patients with TP53 Disrupted B Cell Prolymphocytic Leukemia

18 f-FDG PET-CT Assessment of Responses to Salvage Therapy and Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only